Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has reported a significant stock transaction involving one of its directors, Marijn E. Dekkers. According to the latest filing, Dekkers sold a total of 265,000 shares of Class A Common Stock at a weighted average price of $0.8303 per share. The transaction resulted in a total sale value exceeding $220,000.
The shares were sold in multiple transactions, with prices ranging from $0.8233 to $0.8387. The filing indicates that Dekkers is willing to provide full information regarding the number of shares sold at each separate price within the specified range, upon request.
Following this sale, Dekkers still holds a substantial number of shares in Ginkgo Bioworks. The report includes a footnote stating that his ownership includes 464,481 earn-out shares that are set to vest if the company's stock reaches certain price thresholds by September 16, 2026. Additionally, Dekkers is associated with Novalis LifeSciences Investments I, L.P., and is reported to have sole voting and dispositive power over the shares held by Novalis LifeSciences.
Investors often keep a close eye on insider transactions as they can provide insights into the company's performance and prospects as perceived by its top executives. The sale by Dekkers may draw particular interest given his role within the company and the significant amount of the transaction.
InvestingPro Insights
As Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) faces scrutiny following insider transactions, investors are looking for additional insights into the company's financial health and market performance. According to InvestingPro data, Ginkgo Bioworks has a market capitalization of approximately $1.7 billion USD, with a notable gross profit margin of 80.43% for the last twelve months as of Q1 2024. Despite this strong margin, the company has experienced a substantial revenue decline of 46.49% during the same period.
The company's stock has been trading near its 52-week low, with the price at the previous close at $0.81 USD. This reflects a significant downturn, with a 6-month price total return of -47.35% and a year-to-date price total return of -52.33%. These figures underscore the challenges Ginkgo Bioworks has faced in the market recently.
Two InvestingPro Tips that are particularly relevant in the context of the recent insider sale are that Ginkgo Bioworks is not expected to be profitable this year, and analysts anticipate a sales decline in the current year. These factors may offer some explanation for the director's decision to sell shares. For investors seeking a deeper dive into the company's outlook, there are an additional 9 InvestingPro Tips available, which can provide a more comprehensive analysis of Ginkgo Bioworks' financial and market position. Interested readers can access these tips by visiting InvestingPro, and can take advantage of a special offer using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.